Recap: Earlier Detection May Be Key to Treatment Advances in Chronic GVHD
May 25, 2022

An expert in hematology/oncology, Dr Yi-Bin Chen, provides insight on chronic GvHD, with a focus on early detection of disease and therapeutic options for the management of steroid-refractory chronic GvHD.

Alina Markova, MD, on the Safety Profile of Topical Ruxolitinib for Cutaneous Chronic GVHD
May 25, 2022

Alina Markova, MD, highlights the safety and tolerability of topical ruxolitinib INCB018424 phosphate 1.5% cream for patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.

Preoperative Radiotherapy Plus Skin-Sparring Mastectomy and Immediate DIEP Flap Reconstruction Safe, Feasible in Breast Cancer
May 24, 2022

Using skin-sparing mastectomy and immediate deep inferior epigastric perforator flap reconstruction following preoperative radiotherapy was safe and feasible in patients with primary breast cancer.

Darolutamide Yields Positive, Long-Lasting Outcomes in nmCRPC With or Without Prior Local Therapy
May 24, 2022

Three year follow-up findings from a post hoc analysis of the phase 3 ARAMIS trial indicated that darolutamide maintained a survival benefit regardless of prior local therapy for patients with nonmetastatic castration-resistant prostate cancer.

Tucatinib Plus Trastuzumab Yields Positive Topline Data in Phase 2 MOUNTAINEER Trial for HER2+ mCRC
May 24, 2022

In the phase 2 MOUNTAINEER trial, patients with previously treated HER2-positive metastatic colorectal cancer who were treated with tucatinib plus trastuzumab were shown to have an improved objective response rate.

Recap: Advances in Systemic Therapy of Differentiated Thyroid Cancer Across Lines of Therapy
May 24, 2022

Lori Wirth, MD, provides an overview of differentiated thyroid cancer including treatment options that are currently available, as well as sharing insights on emerging therapies.

Case Presentation 2: Transplant-Ineligible NDMM and Treatment With the DRd Regimen
May 24, 2022

Experts review a second patient case wherein transplant-ineligible newly diagnosed multiple myeloma was treated with the daratumumab, lenalidomide and dexamethasone regimen and how updated data from the MAIA trial can be incorporated into clinical practice.

ELEVATE-RR: Efficacy Data
May 24, 2022

Experts discuss efficacy data from the ELEVATE-RR trial on the Bruton tyrosine kinase inhibitors acalabrutinib vs ibrutinib.

Role for Transplantation and Maintenance Therapy in NDMM
May 24, 2022

Considerations for assessing eligibility of patients for transplantation for NDMM and how maintenance therapy may be initiated in the post-transplant setting.

Patient Characteristics in ELEVATE-RR
May 24, 2022

Dr Bishop comments on the characteristics of the patients with CLL who were enrolled in the ELEVATE-RR trial.